Perrigo Company plc (PRGO)

NYSE • Healthcare

$15.96

-$0.41 (-2.5%)

Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$16.22

Day Range$15.88 - $16.33

Avg. Volume (3M)2.5M

Market Cap$2.2B

52 Week Range

$9.23$22.01

Next EarningsIn 10 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$1B100%

Gross Profitminus cost of goods$313.9M31%

Operating Incomeminus R&D and overhead$23.5M2%

Net Incomeminus taxes and the rest$74.5M7%

In plain terms: out of every $100 in revenue, Perrigo Company plc keeps $7 as net profit.

Fundamentals & Financials

Revenue (TTM)

$4.1B

Net Income (TTM)

-$1.7B

EPS (TTM)

-$12.51

ROA (TTM)

-22.8%

Current Ratio

2.32

Dividend Yield

5.79%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-3.4%Q3 2025$0.57

+6.7%Q4 2025$0.8

-3.8%Q1 2026$0.77

+10.3%Q2 2026$0.43

+28.9%Q3 2026$0.5

Nov 4

in 10 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +28.9%

Perrigo Company plc topped consensus on both the top and bottom line in the second fiscal quarter of 2026, reported August 5, as adjusted EPS of $0.50, down about 12% from $0.57 a year ago, beat the $0.31 estimate by about 61% and revenue of about $1.0 billion edged the $1.0 billion consensus by about 1%. Revenue fell about 3% from about $1.1 billion a year earlier, while gross profit came to about $313.9 million, gross margin held near 31%, and operating income was about $23.5 million with operating margin around 2%. Operating cash flow reached about $82.6 million, and the company paid $40.2 million in dividends. Next-period consensus calls for EPS of $0.56 on revenue of $994.9 million.

Next report — what to expect

Perrigo Company plc (PRGO) is set to report earnings on November 4, 2026. Wall Street’s consensus calls for EPS of $0.517 on revenue of $991.5 million; for trailing context, revenue fell -3.2% year over year last quarter. Perrigo has beaten EPS in 5 of its 8 most recent quarters.

View full earnings history

About Perrigo Company plc

Perrigo Company plc develops and sells over-the-counter self-care and consumer health products, making it a healthcare manufacturer focused on branded and store-brand medicines and wellness items. Listed on the NYSE as PRGO, it generated $4.3 billion of revenue in FY2025.

Name

Perrigo Company plc

CEO

Albert A. Manzone

Website

www.perrigo.com

Industry

Healthcare

Year Founded

1887

Employees

8,100

Today's Snapshot

AI-generated

The day ended with PRGO 2.5% lower at 15.96, in line with a weaker sector. Volume was about half of its usual level.

Trading Volume

Below 10d avg (2.4M)

1.1M

vs S&P 500 Today

Underperforming Market

-2.02%

Updated: October 23, 2026 at 20:07 UTC

Technical Indicators

6 Buy2 Neutral0 Sell

PRGO registers as a strong buy on the back of a strengthening trend and clear moving-average support while momentum indicators are constructive. ADX shows a meaningful trend, and MACD is positive while RSI sits in favorable territory, supporting momentum without extreme overbought readings. The current price is above most short, medium and long-term averages including the 200-day, which underscores structural upside, and ATR indicates moderate volatility. Pivot levels sit slightly above the market but do not negate the broader set-up; OBV also signals accumulation. Technical takeaway: Strong Buy — trend-confirmed strength with broad moving-average support and positive momentum.

All signals